Bellerophon Therapeutics Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bellerophon Therapeutics stock.
View analyst ratings for Bellerophon Therapeutics or view top-rated stocks.

Wall Street analysts have given Bellerophon Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bellerophon Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Bellerophon Therapeutics.

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) announced its earnings results on Monday, May, 10th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $0.13.
View Bellerophon Therapeutics' earnings history.

Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BLPH shares have decreased by 31.2% and is now trading at $4.33.
View which stocks have been most impacted by COVID-19.

Bellerophon Therapeutics shares reverse split before market open on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

3 analysts have issued 1-year price objectives for Bellerophon Therapeutics' shares. Their forecasts range from $19.00 to $30.00. On average, they anticipate Bellerophon Therapeutics' stock price to reach $23.67 in the next twelve months. This suggests a possible upside of 446.6% from the stock's current price.
View analysts' price targets for Bellerophon Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Bellerophon Therapeutics include Novan (NOVN), Adamis Pharmaceuticals (ADMP), Oasmia Pharmaceutical AB (publ) (OASMY), Tiziana Life Sciences (TLSA), IMV (IMV), ContraFect (CFRX), Calithera Biosciences (CALA), NeuBase Therapeutics (NBSE), Qilian International Holding Group (QLI), Antibe Therapeutics (ATBPF), SCYNEXIS (SCYX), Oncolytics Biotech (ONCY), Eton Pharmaceuticals (ETON), Flora Growth (FLGC) and DiaMedica Therapeutics (DMAC).
View all of BLPH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

(BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Bellerophon Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.39%), New Mountain Vantage Advisers L.L.C. (2.66%), Renaissance Technologies LLC (2.46%), DAVENPORT & Co LLC (1.04%), Caas Capital Management LP (1.03%) and Northern Trust Corp (0.80%). Company insiders that own Bellerophon Therapeutics stock include Associates Iv L P Venrock, New Mountain Investments Ii, L, Theodore T Wang and Wassim Fares.
View institutional ownership trends for Bellerophon Therapeutics.

BLPH stock was sold by a variety of institutional investors in the last quarter, including New Mountain Vantage Advisers L.L.C., and Northern Trust Corp.
View insider buying and selling activity for Bellerophon Therapeutics or view top insider-selling stocks.

BLPH stock was acquired by a variety of institutional investors in the last quarter, including Caas Capital Management LP, Citadel Advisors LLC, Tudor Investment Corp Et Al, Citadel Advisors LLC, Laurion Capital Management LP, Renaissance Technologies LLC, Squarepoint Ops LLC, and Element Capital Management LLC. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Theodore T Wang, and Wassim Fares.
View insider buying and selling activity for Bellerophon Therapeutics or or view top insider-buying stocks.

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLPH stock can currently be purchased for approximately $4.33.

Bellerophon Therapeutics has a market capitalization of $41.16 million. The biotechnology company earns $-24,730,000.00 in net income (profit) each year or ($3.06) on an earnings per share basis.

Bellerophon Therapeutics employs 21 workers across the globe.

The official website for Bellerophon Therapeutics is www.bellerophon.com.

Bellerophon Therapeutics is headquartered at 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059.

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]